find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04768881 / XPORT-MEL-033
A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN ACTIVELY DIAGNOSED OR RECURRENT ADVANCED MELANOMA
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03486873 / MK3475-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03833167 / MK-3475-630
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT03897881 / MRNA-4157-P201
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
Learn More
Transplant
Phase I/II
Accepting Patients
nct/study# NCT04482699 / RAPA501ALLOCOVID19
RAPA-501-ALLO-COVID-19, PI: Dr. Donato, Title: Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-Allo) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease
Learn More
Transplant
Phase I
Accepting Patients
nct/study# NCT04220190 / RAPA-501-ALS
Phase I Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) for Amyotrophic Lateral Sclerosis
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.